×
About 3,955 results

ALLMedicine™ HER2+ Center

Research & Reviews  1,745 results

Independent validation of the PAM50-based Chemo-Endocrine Score in hormonal receptor po...
https://doi.org/10.1158/1078-0432.CCR-20-4102
Clinical Cancer Research : an Official Journal of the Ame... Pascual T, Fernandez-Martinez A et. al.

Feb 26th, 2021 - We do not yet have validated biomarkers to predict response and outcome within hormone receptor-positive/HER2-positive (HR+/HER2+) breast cancer (BC). The PAM50-based chemo-endocrine score (CES) predicts chemo-endocrine sensitivity in HR+/HER2-neg...

Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown.
https://doi.org/10.1073/pnas.2022830118 10.4155/tde.14.92
Proceedings of the National Academy of Sciences of the Un... Zhang Y, Xie X et. al.

Feb 25th, 2021 - New strategies for cancer immunotherapy are needed since most solid tumors do not respond to current approaches. Here we used epithelial cell adhesion molecule EpCAM (a tumor-associated antigen highly expressed on common epithelial cancers and the...

Association of Obesity with Breast Cancer Outcome in Relation to Cancer Subtypes: A Met...
https://doi.org/10.1093/jnci/djab023
Journal of the National Cancer Institute; Lohmann AE, Soldera SV et. al.

Feb 23rd, 2021 - Obesity at breast cancer (BC) diagnosis has been associated with poor outcome, although the magnitude of effect in different BC subtypes is uncertain. We report on the association of obesity/overweight at diagnosis of non-metastatic BC with diseas...

see more →

Guidelines  43 results

Pyrotinib bests lapatinib in HER2+ metastatic breast cancer
https://www.mdedge.com/hematology-oncology/article/223057/breast-cancer/pyrotinib-bests-lapatinib-her2-metastatic-breast

May 30th, 2020 - The combination of pyrotinib and capecitabine significantly prolonged progression-free survival (PFS), when compared with lapatinib and capecitabine, among patients with previously treated HER2-positive metastatic breast cancer in a phase 3 trial.

Pyrotinib Combo Improves PFS in HER2+ Metastatic Breast Cancer
https://www.onclive.com/conference-coverage/asco-2020/pyrotinib-combo-improves-pfs-in-her2-mbc

May 30th, 2020 - Pyrotinib plus capecitabine achieved a better progression-free survival (PFS) than lapatinib (Tykerb) plus capecitabine in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab and chemotherapy. Results fro...

TRAIN-2: Anthracyclines added toxicity, with no increased efficacy, in HER2+ breast cancer
https://www.mdedge.com/hematology-oncology/article/223040/breast-cancer/train-2-anthracyclines-added-toxicity-no-increased

May 29th, 2020 - Anthracyclines add toxicity with no evidence of improved survival in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy regimen plus dual HER2 blockade, results of a randomized phase 3 trial have suggested.

Tucatinib improves PFS, OS in HER2+ breast cancer with brain metastases
https://www.mdedge.com/hematology-oncology/article/223043/breast-cancer/tucatinib-improves-pfs-os-her2-breast-cancer-brain

May 29th, 2020 - In HER2-positive breast cancer patients with brain metastases treated with trastuzumab and capecitabine, add-on tucatinib increased median overall survival from 12 months to 18.1 months in a phase 2 trial.

HER2+ Colorectal and Gastric/GEJ Cancers Demonstrate Responses to Fam-Trastuzumab Deruxtecan Therapy
https://www.targetedonc.com/view/her2-colorectal-and-gastric-gej-cancers-demonstrate-responses-to-fam-trastuzumab-deruxtecan

May 29th, 2020 - Data from 2 phase 2 trials involving fam-trastuzumab deruxtecan-nxki (Enhertu) revealed the agent’s ability to induce responses in patients with HER2-positive metastatic colorectal cancer (CRC) and advanced gastric or gastroesophageal junction (GE...

see more →

Drugs  15 results see all →

Clinicaltrials.gov  1,917 results

Independent validation of the PAM50-based Chemo-Endocrine Score in hormonal receptor po...
https://doi.org/10.1158/1078-0432.CCR-20-4102
Clinical Cancer Research : an Official Journal of the Ame... Pascual T, Fernandez-Martinez A et. al.

Feb 26th, 2021 - We do not yet have validated biomarkers to predict response and outcome within hormone receptor-positive/HER2-positive (HR+/HER2+) breast cancer (BC). The PAM50-based chemo-endocrine score (CES) predicts chemo-endocrine sensitivity in HR+/HER2-neg...

Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown.
https://doi.org/10.1073/pnas.2022830118 10.4155/tde.14.92
Proceedings of the National Academy of Sciences of the Un... Zhang Y, Xie X et. al.

Feb 25th, 2021 - New strategies for cancer immunotherapy are needed since most solid tumors do not respond to current approaches. Here we used epithelial cell adhesion molecule EpCAM (a tumor-associated antigen highly expressed on common epithelial cancers and the...

Association of Obesity with Breast Cancer Outcome in Relation to Cancer Subtypes: A Met...
https://doi.org/10.1093/jnci/djab023
Journal of the National Cancer Institute; Lohmann AE, Soldera SV et. al.

Feb 23rd, 2021 - Obesity at breast cancer (BC) diagnosis has been associated with poor outcome, although the magnitude of effect in different BC subtypes is uncertain. We report on the association of obesity/overweight at diagnosis of non-metastatic BC with diseas...

see more →

News  235 results

Margetuximab for HER2+ Metastatic Breast Cancer Falls Short
https://www.medscape.com/viewarticle/943233

Jan 6th, 2021 - This transcript has been edited for clarity. Happy holidays, everyone. This is Dr Kathy Miller from Indiana University. I want to make sure you've had a chance to think carefully about the margetuximab approval by the US Food and Drug Administrati...

Margetuximab Approved for HER2+ Metastatic Breast Cancer
https://www.medscape.com/viewarticle/942869

Dec 16th, 2020 - A new monoclonal antibody that targets HER2+ in breast cancer, margetuximab-cmkb (Margenza), has been approved by the Food and Drug Administration (FDA). The new drug is indicated for use in combination with chemotherapy for the treatment of patie...

pCR in HER2+ Breast Cancer Predicts Long-Term Survival
https://www.staging.medscape.com/viewarticle/939526

Oct 20th, 2020 - A pathologic complete response (pCR) to targeted therapy in HER2-positive breast cancer portends good long-term outcomes, according to final results of the phase 3 NeoALTTO/BIG 1-06 trial. In fact, for the majority of women, pCR appears to be a ma...

pCR in HER2+ Breast Cancer Predicts Long-Term Survival
https://www.medscape.com/viewarticle/939526

Oct 20th, 2020 - A pathologic complete response (pCR) to targeted therapy in HER2-positive breast cancer portends good long-term outcomes, according to final results of the phase 3 NeoALTTO/BIG 1-06 trial. In fact, for the majority of women, pCR appears to be a ma...

Fast Five Quiz: HER2+ Breast Cancer
https://reference.medscape.com/viewarticle/936775_4

Sep 13th, 2020 - According to the NCCN Breast Cancer Clinical Practice Guidelines for the management of invasive breast cancer, pertuzumab plus trastuzumab plus a taxane is a preferred systemic therapy regimen for recurrent or stage IV HER2+ breast cancer (Categor...

see more →